AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2931937
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection sclerotherapy (ST)
Trial: 2931937
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy (balloon tamponade and/or vasopression infusion)
Trial: 29678977
Drug: Dexmedetomidine (sleep-inducing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (sleep-inducing dose)
Trial: 24574278
Drug: Xylitol (Xlear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (Xlear Nasal Spray®)
Trial: 12185402
Drug: Hydrocortisone 20
RxNorm normalized name: hydrocortisone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 20 mg administered twice daily for 7 days
Trial: 12185402
Drug: TRH administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH administration after L-tryptophan infusion
Trial: 8527275
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg p.o. daily for 2 weeks
Trial: 8527275
Drug: Isoniazid 300
RxNorm normalized name: isoniazid 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid 300 mg p.o. daily for 1 week
Trial: 2121848
Drug: Prolonged praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged praziquantel courses (initial dose of 40 mg/Kg, followed by 6-monthly full dose)
Trial: 2121848
Drug: Prolonged praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged praziquantel courses (initial dose of 40 mg/Kg, followed by 3-monthly half doses)
Trial: 2121848
Drug: Prolonged praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged praziquantel courses (initial dose of 40 mg/Kg, followed by monthly half doses)
Trial: 2121848
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B complex (placebo)
Trial: 23570248
Drug: Clarithromycin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (7.5 mg/kg/dose every 12 hours)
Trial: 15201240
Drug: Age >=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age >= 65 years, diabetes, previous myocardial infarction, congestive heart failure, use of beta blockers or diuretics at admission, 12 lead ECG ST segment depression at admission, troponin T concentration >= 0.10 microg/l, and >= 1 ST vector magnitude episodes
Trial: 15201240
Drug: Age >=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age >= 65 years, previous myocardial infarction, and troponin T concentration >= 0.10 microg/l
Trial: 29356462
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of 99 Tc-MDP
Trial: 29356462
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of intravenous drip of 99 Tc-MDP and oral meloxicam tablets
Trial: 29356462
Drug: Oral meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral meloxicam tablets
Trial: 19804441
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose fluticasone 100 microg/day with intranasal placebo
Trial: 19804441
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose fluticasone 500 microg/day with intranasal placebo
Trial: 19804441
Drug: Combined fluticasone
RxNorm normalized name: fluticasone, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined fluticasone 100 microg/day with intranasal fluticasone 200 microg/day
Trial: 19804441
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose fluticasone vs Low dose fluticasone
Trial: 19804441
Drug: Combined vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vs Low dose fluticasone
Trial: 8538891
Drug: Verbal medication
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal medication counseling from a pharmacist
Trial: 8538891
Drug: No verbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No verbal medication counseling (uncounseled)
Trial: 1837743
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg IV before cisplatin, then 1 mg/h for 24 hours; oral 8 mg three times daily on days 2-6) plus Dexamethasone (20 mg IV)
Trial: 1837743
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg IV before cisplatin, then 1 mg/h for 24 hours; oral 8 mg three times daily on days 2-6)
Trial: 1837743
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Ondansetron + Dexamethasone)
Trial: 31311668
Drug: Temelimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temelimab at doses of 36, 60, 85, and 110 mg/kg
Trial: 24171301
Drug: Topical ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ivermectin (1% applied at 400 microg/kg, repeated once the following week)
Trial: 24171301
Drug: Permethrin 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 2.5% cream (applied twice at one week intervals)
Trial: 21733058
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg (Alo25) added to Metformin and Pioglitazone
Trial: 21733058
Drug: Pioglitazone 15
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg (Met+Pio45)
Trial: 16400465
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg loading dose before incision, followed by 1 mg/kg/h for 5 hours)
Trial: 16400465
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline bolus and continuous infusion for 5 hours)
Trial: 15262026
Drug: Sedation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation with midazolam elixir
Trial: 15262026
Drug: Analgesia with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesia with morphine sulphate
Trial: 15262026
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with dextromoramide and lorazepam
Trial: 2935644
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg diethylstilbestrol orally 3 times daily
Trial: 2935644
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oral cyproterone acetate daily
Trial: 2935644
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg medroxyprogesterone acetate intramuscularly 3 times weekly for 8 weeks, then 200 mg orally daily
Trial: 2935644
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg diethylstilbestrol
Trial: 2935644
Drug: 560 mg
RxNorm normalized name: spinosad 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 560 mg estramustine phosphate orally for 8 weeks, then 280 mg daily
Trial: 30041701
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (POM) supplementation, 50 ml daily for two months
Trial: 27029363
Drug: High exposed
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High exposed group (average concentration of cadmium >0.40 mg/kg in rice and >1.0 mg/kg in soil)
Trial: 27029363
Drug: Low exposed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low exposed group (average concentration of cadmium 0.15-0.40 mg/kg in rice and 0.5-1.0 mg/kg in soil)
Trial: 25398670
Drug: CC genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC genotype of rs324148
Trial: 25398670
Drug: CC genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC genotype of rs9394992
Trial: 20492853
Drug: Higher-dose paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Higher-dose paliperidone ER (12 mg/d)
Trial: 20492853
Drug: Lower-dose paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lower-dose paliperidone ER (6 mg/d)
Trial: 20492853
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER (both doses)
Trial: 18954708
Drug: Low-dose CBCT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CBCT imaging
Trial: 8800307
Drug: Cadexomer iodine
RxNorm normalized name: Cadexomer Iodine
DrugBank: Cadexomer iodine (DB16572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadexomer iodine ointment (Iodosorb)
Trial: 8800307
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (gentamicin solution, streptodornase/streptokinase, or dry saline gauze)
Trial: 1320306
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (720 EIU, 3 doses, 0, 1 month schedule, booster at month 6)
Trial: 1320306
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (3 consecutive lots)
Trial: 6480953
Drug: Doxepin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (10 mg three times daily)
Trial: 6480953
Drug: Cyproheptadine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (4 mg three times daily)
Trial: 6480953
Drug: Hydroxyzine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (10 mg three times daily)
Trial: 6480953
Drug: Cinnarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine (10 mg three times daily)
Trial: 26973262
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for 8 weeks in addition to routine postoperative treatment
Trial: 26973262
Drug: Routine postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine postoperative treatment only (Control)
Trial: 22773286
Drug: Antenatal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal treatment of maternal periodontitis
Trial: 22773286
Drug: Postpartum treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postpartum treatment of maternal periodontitis
Trial: 21733413
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care program from a clinical pharmacist
Trial: 16675610
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 mug once daily for 7-10 days
Trial: 12001701
Drug: Immunoablative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoablative therapy including high dose cytotoxic agents and hematopoietic autologous stem‐cell rescue
Trial: 12001701
Drug: Non‐myeloablative allogeneic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐myeloablative allogeneic transplantation and sub‐myeloblative high dose cyclophosphamide without stem cell support
Trial: 9572809
Drug: Sucrose solution
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose solution (0.75 g/kg body wt)
Trial: 8586807
Drug: NG‐monomethyl‐L‐arginine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl‐L‐arginine (250 mg by intravenous infusion for 5 min)
Trial: 779796
Drug: Cyclophosphamide (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (average dose: 1.8 mg/kg/day)
Trial: 27842926
Drug: No jejunal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No jejunal supplement (Control)
Trial: 23329881
Drug: neoadjuvant chemotherapy+rh‐endostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy+rh‐endostatin
Trial: 17277036
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg vildagliptin daily
Trial: 17277036
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg vildagliptin daily
Trial: 15489367
Drug: Low fluoride
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fluoride mouthrinse/toothpaste treatment regime
Trial: 15489367
Drug: Non-active control
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active control combination
Trial: 11574431
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (multiple daily injections or continuous subcutaneous infusion with frequent blood-glucose testing)
Trial: 11574431
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (1-2 injections of insulin per day)
Trial: 11574431
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy and Conventional therapy
Trial: 9316669
Drug: Clonazepam (0.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (0.5-2.5 mg/day)
Trial: 28035016
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion (160 mg, range 110-200 mg in the 5 min before exercise)
Trial: 22365565
Drug: Propranolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol infusion
Trial: 28035016
Drug: Esmolol maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol maintenance infusion (0.2 mg·kg total body mass-1·min-1)
Trial: 28035016
Drug: Esmolol and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol and saline infusion during epinephrine infusion
Trial: 26046585
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of water
Trial: 21221002
Drug: Subcutaneous continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous continuous glucose monitoring
Trial: 18641196
Drug: Weekly folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly folic acid supplementation (5000 or 2800 microg)
Trial: 18641196
Drug: Daily folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily folic acid supplementation (400 or 200 microg)
Trial: 18641196
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily and weekly iron, zinc, and vitamin B‐12 provided)
Trial: 12048138
Drug: Bezafibrate treatment
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate treatment
Trial: 30338680
Drug: Robuvit 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robuvit 300 mg/day
Trial: 27001568
Drug: Farletuzumab 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Farletuzumab 1.25 mg/kg
Trial: 27001568
Drug: Farletuzumab 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Farletuzumab 2.5 mg/kg
Trial: 21486536
Drug: Dutasteride (2mg/g)
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dutasteride (2mg/g)
Trial: 21486536
Drug: Progesterone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (40 mg)
Trial: 12099160
Drug: Policosanol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol (5 mg/day, increased to 10 mg/day if total cholesterol > 6.1 mmol/L after 6 months)
Trial: 28099300
Drug: Plate fixation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plate fixation and Nonoperative treatment
Trial: 12750100
Drug: argon green
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: argon green laser treatment (multiple 100‐micro m spots at least 750 micro m from the center of the fovea)
Trial: 12750100
Drug: argon green
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: argon green laser treatment
Trial: 12750100
Drug: argon green
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: argon green laser treatment (higher-intensity laser burns)
Trial: 12750100
Drug: choroidal neovascularization
RxNorm normalized name: Antineovascularisation agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: choroidal neovascularization in each treatment group
Trial: 11097147
Drug: DIC‐effervesc (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIC‐effervesc (50 mg diclofenac Na)
Trial: 11097147
Drug: DIC‐enteric (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIC‐enteric (50 mg diclofenac Na)
Trial: 9133184
Drug: 0.04 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mg/kg neostigmine (group N25)
Trial: 9133184
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg edrophonium (group E25)
Trial: 9133184
Drug: 0.04 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mg/kg neostigmine (group N5)
Trial: 9133184
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg edrophonium (group E5)
Trial: 7756472
Drug: Aerosolized pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized pentamidine (300 mg every 4 weeks)
Trial: 8442918
Drug: Cotrimoxazole (160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (160/800 mg 3 days a week)
Trial: 8442918
Drug: Dapsone plus
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone plus pyrimethamine (100 and 25 mg weekly)
Trial: 24993763
Drug: Internet-delivered Acceptance
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered Acceptance and Commitment Therapy (ACT) intervention, 8 sessions over 8 weeks
Trial: 20880720
Drug: EMG‐BF treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG‐BF treatment
Trial: 10440593
Drug: PPA 12.5
RxNorm normalized name: APAP 325/CTM 2/PPA 12.5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA 12.5 mg tid
Trial: 10440593
Drug: PPA 25
RxNorm normalized name: APAP 650/CTM 4/PPA 25MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA 25 mg tid
Trial: 10440593
Drug: Pseudoephedrine 120
RxNorm normalized name: CTM 8/PSEUDOEPHEDRINE 120MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 120 mg/day
Trial: 10440593
Drug: PPA 75
RxNorm normalized name: Guaifenex PPA 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA 75 mg/day with benzocaine gum 96 mg/day
Trial: 10440593
Drug: Benzocaine gum
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzocaine gum 96 mg/day
Trial: 15504857
Drug: Caspofungin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin alone (50 mg IV once daily)
Trial: 15504857
Drug: Caspofungin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin with nelfinavir (1,250 mg orally twice daily)
Trial: 15504857
Drug: Caspofungin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin with rifampin (600 mg orally once daily)
Trial: 15504857
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg orally once daily)
Trial: 15504857
Drug: Caspofungin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (70 mg daily)
Trial: 9013456
Drug: Preemptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive therapy (Ganciclovir administered intravenously for 21 days upon detection of CMV viremia)
Trial: 9013456
Drug: Deferred therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred therapy (Ganciclovir administered intravenously for 21 days upon detection of CMV viremia associated with a CMV syndrome)
Trial: 9013456
Drug: Preemptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive therapy (Ganciclovir use)